Other Information.
+Added: During the three months ended June 30, 2026 , Deborah Messemer , a member of the Company’s Board of Directors , adopted a written trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: The trading arrangement provides for the sale of up to 47,700 shares of the Company’s common stock to be acquired upon the vesting of restricted stock units, representing 50% of the gross number of shares scheduled to vest on December 18, 2026 and June 18, 2027, with sales to occur at market prices during the applicable sale periods specified in the trading arrangement.
+Added: The trading arrangement is scheduled to terminate on June 30, 2027 , or earlier upon the completion of all sales under the trading arrangement or upon the occurrence of certain other termination events specified in the trading arrangement.
+Added: No other director or officer adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended June 30, 2026.
Description of document
3 unchanged sentences
001-38693), filed with the SEC on June 17, 2022).
+Added: 3.3 Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-38693), filed with the SEC on June 22, 2026).
3.4 Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No.
3 unchanged sentences
333-227333), filed with the SEC on October 2, 2018).
+Added: 10.1 Termination Agreement, dated May 12, 2026, by and between the Registrant, Overland Therapeutics (SH) Co.
+Added: and Overland Therapeutics Inc .
+Added: 10.2 Second Amended and Restated Shareholders’ Agreement, dated May 12, 2026, by and between the Registrant, Overland Therapeutics Inc.
+Added: and HH BioPharma Holdings Ltd.
10.3+ Consulting Agreement, effective as of August 9, 2018, by and between the Registrant and Bellco Capital LLC, as amended.
+Added: (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-38693), filed with the SEC on May 13, 2026).
+Added: 10.4+ Employment Agreement, dated May 28, 2026, by and between the Registrant and Zachary Roberts , M.D., Ph.D.
+Added: 10.5 First Amendment to the Amended and Restated Strategic Collaboration Agreement, effective as of August 5, 2025, by and between the Registrant and Foresight Diagnostics, Inc.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
11 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: May 13, 2026 By:
−Removed: /s/ David Chang
−Removed: David Chang, M.D., Ph.D.
+Added: August 12, 2026 By:
+Added: /s/ Zachary Roberts
+Added: Zachary Roberts, M.D., Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: May 13, 2026 By:
+Added: August 12, 2026 By:
/s/ Geoffrey Parker
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.